OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ZCMD
Zhongchao Inc.
There isn't enough reported data to score ZCMD yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ZCMD Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ZCMD's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ZCMD PE Valuation
ZCMD has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ZCMD Forward outlook
There aren't enough analyst estimates for ZCMD to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ZCMD in the latest year-over-year earnings comparison.
ZCMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | -$178.56 | +$6,300.19 |
| Q2 2024 | -$3,755.71 | +$604.13 |
| Q4 2023 | -$6,478.75 | -$4,797.31 |
| Q2 2023 | -$4,359.84 | -$3,904.65 |
| Q4 2022 | -$1,681.44 | -1301% |
| Q4 2021 | $140.01 | -95% |
| Q4 2020 | $2,723.04 | -2.1% |
ZCMD lost $178.56 per share over the past year, a smaller loss than the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ZCMD in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ZCMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $5.8M | -23% |
| Q2 2025 | $5.6M | -33% |
| Q4 2024 | $7.5M | -17% |
| Q2 2024 | $8.3M | -20% |
| Q4 2023 | $9.1M | +32% |
| Q2 2023 | $10.4M | +42% |
| Q4 2022 | $6.9M | -11% |
| Q2 2022 | $7.3M | -15% |
ZCMD's revenue has slid since its 2020 peak: $6M last quarter, down 36% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -92% | -12 points |
| Q2 2025 | -16% | +42 points |
| Q4 2024 | -3.9% | +39 points |
| Q2 2024 | -0.6% | -5.8 points |
| Q4 2023 | -80% | -65 points |
| Q2 2023 | -58% | -70 points |
| Q4 2022 | -43% | -70 points |
| Q2 2022 | 5.2% | -24 points |
ZCMD's operating margin was −92% last quarter, down 12 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
ZCMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$3.2M | -399% |
| Q2 2024 | -$1.3M | +$579.7K |
| Q4 2023 | $1.1M | +$2.5M |
| Q2 2023 | -$1.9M | -$1M |
| Q4 2022 | -$1.5M | -210% |
| Q2 2022 | -$821.9K | -$561.4K |
| Q4 2021 | $1.3M | +$2.5M |
| Q4 2020 | -$1.2M | -1360% |
ZCMD has burned cash in most quarters: −$5M over the past year, against −$1M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ZCMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +22 shares |
| 1 year | +1.5% | +26 shares |
ZCMD has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ZCMD Net Leverage
ZCMD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ZCMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.0 | Oversold |
| Stochastic | 3.0 | Oversold |
ZCMD's weekly RSI is 23 (oversold) and its Stochastic is 3 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ZCMD PE vs Healthcare Sector
| Metric | ZCMD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ZCMD has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ZCMD on trend strength, trading above more of its moving averages.
ZCMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.35 | 31% below |
| 20 week MA | $1.90 | 51% below |
| 50 week MA | $251.7 | 100% below |
| 100 week MA | $981.6 | 100% below |
| 200 week MA | $5,187.8 | 100% below |
ZCMD is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ZCMD on returns for 2026, with the stronger performance.
ZCMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58,180.8 | $26,188.8 | -55% |
| 2021 | $26,188.8 | $27,081.6 | +3.4% |
| 2022 | $27,081.6 | $17,260.8 | -36% |
| 2023 | $17,260.8 | $5,224.4 | -70% |
| 2024 | $5,224.4 | $2,455.2 | -53% |
| 2025 | $2,455.2 | $757.4 | -69% |
| 2026 YTD | $757.4 | $0.93 | -100% |
ZCMD has finished four years in a row lower, and it's down 100% so far in 2026.